Wednesday, August 6, 2025 8/6/2025

Development of anticoagulant sulfated glycans

Award Number: R44GM148100
ORGANIZATION: NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES
OPDIV: NIH
AWARD CLASS: DISCRETIONARY
AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)
PERIOD OF PERFORMANCE START DATE: 08/16/2023
PERIOD OF PERFORMANCE END DATE: 08/31/2026

Group Awards By:

View Award Description

Development of anticoagulant sulfated glycans - Sulfated glycan 8-mer is a carbohydrate-based compound with anticoagulant activity. The goal of this project is to replace animal-sourced low-molecular weight heparin (LMWH) with the 8- mer. LMWHs are partially depolymerized natural products of heparin, which are isolated from porcine intestine. A worldwide distribution of contaminated heparin in 2007 was associated with 85 deaths in the US, which is impacted the supply of LMWH. LMWHs are complex mixtures, having average molecular masses of 3500-6000 Daltons, corresponding to 12-20 saccharide units. The production of homogeneous LMWHs has not been possible due to difficulties in the synthesis. Glycan Therapeutics proposes to use an innovative chemoenzymatic approach to prepare synthetic heparin to substitute animal-sourced LMWH. The 8-mer product possesses following properties compared with other candidates: relative short synthesis, fast clearance property and low risk for heparin-induced thrombocytopenia. Two specific aims are proposed. Aim 1 is to scale up the synthesis of 8-mer by 10-fold in the phase I funding period and 100-fold in the phase II funding period. Aim 2 is to conduct the pharmacodynamic analysis of 8-mer and enoxaparin in advanced animal models using the quantitative LC-MS/MS method. In phase I funding period, the focus is on method development for analyzing 8-mer and enoxaparin in a mouse model. In the phase II funding period, we will analyze the pharmacodynamics of 8-mer and enoxaparin in a nonhuman primate model. The completion of this project will modernize this century-old drug with improved safety and anticoagulant properties.


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2024 ( Subtotal = $1,090,101 )
2024	2024	GLYCAN THERAPEUTICS CORPORATION	617 HUTTON ST	RALEIGH	NC	27606	WAKE	USA	Biomedical Research and Research Training	001	2	9/19/2024	EXTENSION WITH OR WITHOUT FUNDS	$942,883
2024	2024	GLYCAN THERAPEUTICS CORPORATION	617 HUTTON ST	RALEIGH	NC	27606	WAKE	USA	Biomedical Research and Research Training	002	2	9/24/2024	EXTENSION WITH OR WITHOUT FUNDS	$147,420
2024	2023	GLYCAN THERAPEUTICS CORPORATION	617 HUTTON ST	RALEIGH	NC	27606	WAKE	USA	Biomedical Research and Research Training	000	1	9/4/2024	NEW	-$202
														Subtotal = $1,090,101

Issue Date FY: 2023 ( Subtotal = $355,989 )
2023	2023	GLYCAN THERAPEUTICS CORPORATION	617 HUTTON ST	RALEIGH	NC	27606	WAKE	USA	Biomedical Research and Research Training	000	1	8/15/2023	NEW	$355,989
														Subtotal = $355,989

Grand Total All Awards = $1,446,090

Top

All Categories

About

Search

Reports

Data Submission

Award Information

Development of anticoagulant sulfated glycans

Award Number: R44GM148100

ORGANIZATION: NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES

OPDIV: NIH

AWARD CLASS: DISCRETIONARY

AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

PERIOD OF PERFORMANCE START DATE: 08/16/2023

PERIOD OF PERFORMANCE END DATE: 08/31/2026

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer